Additionally, colchicine (a drug with broad anti-inflammatory effects, including inhibitory effects on the NLRP3 inflammasome)203 and canakinumab (inhibition of IL-1β)204 have shown efficacy in preventing major adverse cardiovascular events in phase III trials in patients with ischemic heart disease. This evidence concerns the gene NLRP3 and coronary artery disorder.